Added to YB: 2026-05-08
Pitch date: 2026-05-01
HLN [neutral]
Haleon plc
+1.95%
current return
Author Info
No bio for this author
Company Info
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Market Cap
GBP 29.7B
Pitch Price
GBP 3.29
Price Target
N/A
Dividend
2.13%
EV/EBITDA
13.24
P/E
18.05
EV/Sales
3.35
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 1/5/2026 - HLN – Q1 trading update; Cold and flu
HLN (update): Q1 organic rev +2.2% (price +2.4pts, vol -0.2pts) on mild cold/flu season; Respiratory -3.4%, Oral +8.3%. Reaffirms FY guidance 3-5% organic growth (likely low end), HSD earnings growth at CER. Medium term: 4-6% organic, HSD earnings. Cash generative power brands, aging/health trends. 15.1x 2027 EPS, 2.6% yield not expensive.
Read full article (1 min)